Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases
Cardiovascular disease remains a leading cause of mortality worldwide. Unresolved inflammation plays a critical role in cardiovascular diseases development. Specialized Pro-Resolving Mediators (SPMs), derived from long chain polyunsaturated fatty acids (LCPUFAs), enhances the host defense, by resolv...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/10/6/933 |
| _version_ | 1797530848248987648 |
|---|---|
| author | Andrea Gila-Diaz Gloria Herranz Carrillo Pratibha Singh David Ramiro-Cortijo |
| author_facet | Andrea Gila-Diaz Gloria Herranz Carrillo Pratibha Singh David Ramiro-Cortijo |
| author_sort | Andrea Gila-Diaz |
| collection | DOAJ |
| description | Cardiovascular disease remains a leading cause of mortality worldwide. Unresolved inflammation plays a critical role in cardiovascular diseases development. Specialized Pro-Resolving Mediators (SPMs), derived from long chain polyunsaturated fatty acids (LCPUFAs), enhances the host defense, by resolving the inflammation and tissue repair. In addition, SPMs also have anti-inflammatory properties. These physiological effects depend on the availability of LCPUFAs precursors and cellular metabolic balance. Most of the studies have focused on the impact of SPMs in adult cardiovascular health and diseases. In this review, we discuss LCPUFAs metabolism, SPMs, and their potential effect on cardiovascular health and diseases primarily focusing in neonates. A better understanding of the role of these SPMs in cardiovascular health and diseases in neonates could lead to the development of novel therapeutic approaches in cardiovascular dysfunction. |
| first_indexed | 2024-03-10T10:35:50Z |
| format | Article |
| id | doaj.art-201d75bdc9e44ec39fa33510e72df577 |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-10T10:35:50Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-201d75bdc9e44ec39fa33510e72df5772023-11-21T23:19:14ZengMDPI AGAntioxidants2076-39212021-06-0110693310.3390/antiox10060933Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and DiseasesAndrea Gila-Diaz0Gloria Herranz Carrillo1Pratibha Singh2David Ramiro-Cortijo3Department of Physiology, Faculty of Medicine, Universidad Autónoma de Madrid, C/Arzobispo Morcillo 2, 28029 Madrid, SpainDivision of Neonatology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), C/Profesor Martin Lagos s/n, 28040 Madrid, SpainDivision of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USADivision of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USACardiovascular disease remains a leading cause of mortality worldwide. Unresolved inflammation plays a critical role in cardiovascular diseases development. Specialized Pro-Resolving Mediators (SPMs), derived from long chain polyunsaturated fatty acids (LCPUFAs), enhances the host defense, by resolving the inflammation and tissue repair. In addition, SPMs also have anti-inflammatory properties. These physiological effects depend on the availability of LCPUFAs precursors and cellular metabolic balance. Most of the studies have focused on the impact of SPMs in adult cardiovascular health and diseases. In this review, we discuss LCPUFAs metabolism, SPMs, and their potential effect on cardiovascular health and diseases primarily focusing in neonates. A better understanding of the role of these SPMs in cardiovascular health and diseases in neonates could lead to the development of novel therapeutic approaches in cardiovascular dysfunction.https://www.mdpi.com/2076-3921/10/6/933oxylipinsspecialized pro-resolving mediatorslong chain polyunsaturated fatty acidsnewbornpremature infantcardiovascular diseases |
| spellingShingle | Andrea Gila-Diaz Gloria Herranz Carrillo Pratibha Singh David Ramiro-Cortijo Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases Antioxidants oxylipins specialized pro-resolving mediators long chain polyunsaturated fatty acids newborn premature infant cardiovascular diseases |
| title | Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases |
| title_full | Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases |
| title_fullStr | Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases |
| title_full_unstemmed | Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases |
| title_short | Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases |
| title_sort | specialized pro resolving lipid mediators in neonatal cardiovascular physiology and diseases |
| topic | oxylipins specialized pro-resolving mediators long chain polyunsaturated fatty acids newborn premature infant cardiovascular diseases |
| url | https://www.mdpi.com/2076-3921/10/6/933 |
| work_keys_str_mv | AT andreagiladiaz specializedproresolvinglipidmediatorsinneonatalcardiovascularphysiologyanddiseases AT gloriaherranzcarrillo specializedproresolvinglipidmediatorsinneonatalcardiovascularphysiologyanddiseases AT pratibhasingh specializedproresolvinglipidmediatorsinneonatalcardiovascularphysiologyanddiseases AT davidramirocortijo specializedproresolvinglipidmediatorsinneonatalcardiovascularphysiologyanddiseases |